Case report: Camrelizumab associated with central retinal vein occlusion

• DOI: 10.3389/fimmu.2022.1025125
• Publication Date: 2022-11-23T04:56:30Z
• Authors: Yixiang Zhan; Weipeng Zhao; Kemin Ni; Zhaoce Liu; Yanjun Su; Xichuan Li; Heng Zhang; Chunze Zhang
• Keywords: lung cancer; 03 medical and health sciences; vitreous hemorrhage; 0302 clinical medicine; camrelizumab; central retinal vein occlusion; Immunology; case report; immunotherapy; Immunologic diseases. Allergy; RC581-607; 3. Good health

Immunotherapy has revolutionized cancer treatment and become one of the five pillars therapy. The clinical applications immunotherapy have been adapted to range from management melanoma most tumor types. As immunotherapies expand, understanding treatment-related adverse events these drugs becomes critical in practice. We report a rare case ocular immune-related side effects associated with camrelizumab that resulted vision loss. A 56-year-old male patient was diagnosed small cell lung cancer. involved porta pulmonis mediastinum upon initial diagnosis; therefore, surgery not possible. Upon receiving 10th session 200 mg, patient’s visual acuity began decrease his right eye central retinal vein occlusion. Optical coherence tomography revealed significant cystoid exudation macular area vitreous hemorrhage. underwent vitrectomy, phacoemulsification intraocular lens implantation after symptom onset. Following surgery, limitedly restored. This is first China occlusion hemorrhage anti-PD-1 therapy, ultimately leading blindness. Although rare, practitioners should be concerned about develop high index suspicion for this possibility since ophthalmic manifestations are rapidly detected, closely monitored, appropriately managed treatable.